Search clinical trials for: Trilaciclib Envafolimab Docetaxel

Total 2344 results

Fudan University

Not yet recruiting

Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC

Advanced Non-Small Cell Lung Cancer
Henan Cancer Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Xinxiang Medical...

Not yet recruiting

Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma

Osteosarcoma

China
UNC Lineberger Comprehensive Cancer Center
G1 Therapeutics, Inc.

Recruiting

Study of Trilaciclib and Lurbinectidin

Lung Cancer | Small-cell Lung Cancer

United States
Anhui Provincial Cancer Hospital

Not yet recruiting

A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
Fudan University

Not yet recruiting

Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer

Locally Advanced Rectal Carcinoma | MSI-High
The First Affiliated Hospital of Xiamen University

Active, not recruiting

Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC

Non-small Cell Lung Cancer Stage IV

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Solid Tumor

China
Northern Jiangsu Province People's Hospital

Recruiting

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

NSCLC

China
Peking Union Medical College Hospital

Not yet recruiting

Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Non-small Cell Lung Cancer
Hairong Liu

Not yet recruiting

Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

Efficacy and Safety
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Breast Neoplasm
Jiangsu Cancer Institute & Hospital

Not yet recruiting

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Biliary Tract Cancer
G1 Therapeutics, Inc.
Bionical Emas

Approved for marketing

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Small Cell Lung Cancer | Chemotherapeutic Toxicity | Myelosuppression Adult
Chipscreen Biosciences, Ltd.

Active, not recruiting

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Non Small Cell Lung Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase I Trial of Envafolimab for Healthy Male Subjects

Healthy Male

China
Anhui Chest Hospital

Not yet recruiting

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (PRESERVE 4)

NSCLC | Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States
Sir Run Run Shaw Hospital

Recruiting

Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma (RECMULRA-TNT)

Rectal Cancer

China
Sir Run Run Shaw Hospital

Recruiting

Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

Rectal Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Advanced Endometrial Cancer

China
Sun Yat-sen University

Recruiting

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Induction Chemotherapy | Locally Advanced Nasopharyngeal Carcinoma | PD-L1 | Envafolimab

China
Eastern Hepatobiliary Surgery Hospital

Recruiting

Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC

Gallbladder Cancer

China
Sun Yat-sen University

Recruiting

Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

Colon Cancer | Neoadjuvant Therapy | Immunotherapy

China
Taixing People's Hospital

Recruiting

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

NSCLC

China
Hebei Medical University Fourth Hospital

Not yet recruiting

A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

Epithelial Ovarian Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC

Lung Neoplasms
Shanghai 6th People's Hospital

Recruiting

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

China
Liangjun Zhu M.M.
Zhangjiagang First People's Hospital

Recruiting

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Metastatic or Recurrent Gastric Adenocarcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
G1 Therapeutics, Inc.

Completed

Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study

Extensive-stage Small-cell Lung Cancer

China
Azaya Therapeutics, Inc.

Completed

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor | Non-Small Cell Lung

United States
Fujian Medical University Union Hospital

Not yet recruiting

Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer

Immunotherapy;Envafolimab; Esophageal Cancer
Korean Breast Cancer Study Group

Unknown

A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer (STORM)

Metastatic Breast Cancer | Recurrent Breast Cancer

Korea, Republic of
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1)

Colorectal Cancer Metastatic | Chemotherapeutic Toxicity | Myelosuppression-Adult

China, Spain, United States, Hungary, United Kingdom, Poland, Ukraine, Italy
Chongqing University Cancer Hospital

Not yet recruiting

Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Yunnan Cancer Hospital
Beijing Bethune Charitable Foundation

Recruiting

Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer (ESTIMATE)

Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer

China
Nereus Pharmaceuticals, Inc.

Completed

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Cancer

United States, Australia, India, Chile, Brazil, Argentina
Tracon Pharmaceuticals Inc.

Active, not recruiting

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC)

Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma

United States, United Kingdom
Zhejiang University

Completed

Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients (CISLD-12)

Advanced Hepatocellular Carcinoma

China
G1 Therapeutics, Inc.

Active, not recruiting

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Fudan University

Unknown

A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC

Gastric Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric

Radiotherapy | Immunotherapy | Gastric/Gastroesophageal Junction Adenocarcinoma
Sun Yat-sen University

Not yet recruiting

Myeloprotection With Trilaciclib in Pan-cancer Population

Cervical Cancer | Breast Cancer | Non-Small Cell Lung Cancer | Endometrial Cancer | Head And Neck Squamous Cell Carcinomas

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC

Pancreatic Cancer | Capecitabine | Radiotherapy | Envafolimab

China
LaNova Medicines Limited

Suspended

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Malignant Tumors

China
Academy Military Medical Science, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer

Advanced Breast Cancer
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (PRESERVE3)

Bladder Cancer | Urothelial Carcinoma | Chemotherapy-induced Neutropenia | Myelosuppression Adult | Metastatic Bladder Cancer

Hungary, Spain, United States, France, Georgia
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China

3

Subscribe